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To the Editor, Problems with the Beckman AccuTnI assay (Beckman Coulter, Brea, CA, USA) are well documented, specifically false-positive results, which are predominantly due to the lack of robustness of the wash process [1, 2] . Our review of results from the last 2.5 years shows that significantly or immediately medically actionable false-positive results occur at a frequency of 1/600 samples. This is a decrease from when we originally implemented the assay, which is a result of improvements in laboratory sample-handling processes and Beckman technical upgrades on the analyzers. Such inappropriate results have caused laboratories to adopt workarounds, which include running specimens in duplicate by the reflex function [2] to minimize error rate, potential profound clinical implications for patients, and negative impact on the laboratory, health-care providers, and Beckman. The release of the new formulation, AccuTnI+3, has been awaited. It has an improved low-end analytical performance, with a 10% CV at 0.018 μg/L [95% confidence interval (CI) 8-25], 99th percentile of 0.022 μg/L (95% CI 0.011-0.034), and limit of detection (LoD) of 0.012 μg/L [3] . This study also shows that the measurable values between the LoD and the 99th percentile were found on 62% of samples [3] . However, whether the robustness of the assay has improved as a result of the altered mixing and probe wash process changes has not been evaluated [3] .
In our experience, specimen quality and wash robustness are the primary causes of the artifactual cardiac troponin I (cTnI) results. The artifactual results occur in both serum and lithium heparin plasma [4] . Hence, we wanted to test the effects of insoluble fibrin and carryover effects actively based on our previously published protocols [1, 2] . This time, both the Access 2 and the DxI800 analyzers were evaluated using the exact same specimens. These experiments were conducted without running any other specimens at the same time-frame on the analyzers. To test the DxI800 analyzer effectively, analysis of the specimens was performed using only a single pipettor, disabling the other three pipettors. This was to simplify the assessment of the effectiveness of the wash processes of the pipettor.
The project was approved by the Princess Alexandra Hospital Ethics Committee. Carryover was performed using four different concentrations of cTnI encountered in patient specimens (Table 1) . A low TnI concentration pool collected in Greiner serum tubes (Cat No. 456078; Geiner Bio-One, Kremsmünster, Austria) was prepared from fresh serum specimens in the 99th percentile range stated by Moretti et al. [3] . The order of analysis was the same as previously published, that is, duplicate analysis of the low-quality control, triplicate analysis of the pool, singlicate analysis of the high sample, triplicate analysis of the low pool, and duplicate analysis of the low-quality control. The target mean ± standard deviation used for the quality control was 0.036 ± 0.004 μg/L for the Access 2 analyzer and 0.042 ± 0.004 μg/L for the DxI800 analyzer. The difference of approximately 17% in the means suggests that if the same 99th percentile is adopted, there will be differences in the classification and treatment of patients, which additionally may present confusion should results be used interchangeably between the two analyzers in a single episode.
The upper linearity limit for the AccuTnI+3 assay is set by Beckman at 95 and 74 μg/L for Access 2 and DxI800, respectively. Samples above these concentrations were diluted to provide the results. The carryover study results e102 Dimeski et al.: False-positive results with AccuTnI+3 assay demonstrated that specimens with AccuTnI+3 concentration of < 389 μg/L for the Access 2 analyzer did not cause false-positive results, whereas specimens with much lower cTnI concentration are very likely to cause false-positive results on the DxI800 analyzer if the same pipettor is used to sample specimens with such high cTnI results immediately followed by specimens with cTnI concentration values less than the 99th percentile. However, with the DxI800 using four pipettors, the carryover problem would be decreased, as it is less likely that the same pipettor will be used to sample a subsequent specimen for cTnI analysis after a high-concentration specimen.
Data indicated that the Access 2 analyzer method changes were more effective in minimizing carryover. In our hospital, with major cardiac services using the AccuTnI method, the carryover frequency based on specimens with cTnI results > 300 μg/L is 1/1500 cTnI requests. As previously pointed out, major difficulty arises in identifying erroneous cTnI results when specimens not requested for cTnI but with grossly elevated cTnI concentration are analyzed for other analytes and are followed by specimens requested for cTnI with concentration less than the 99th percentile [1] . For the first of the insoluble fibrin experiments, a pooled lithium heparin plasma specimen collected in Greiner lithium heparin tubes (Cat No. 456083) with a cTnI concentration less than the 99th percentile was used. The pooled specimen was analyzed 12 times: 10 times with fibrin mesh intact and 2 times following re-centrifugation to provide a clean aliquot. The clean aliquot results were 0.011 and 0.011 μg/L for Access 2 and 0.024 and 0.014 μg/L for DxI800. These results suggest that Access 2 is more precise at this concentration or that the specimen still contains intact fibrin mesh that was not removed by the DxI8000 wash process. The 10 replicates produced the following result ranges: Access 2, 0.019-0.030 μg/L; DxI800, 0.025-1.061 μg/L. These results further support that the Access 2 wash process is more robust than that of DxI800, thus giving a much lower range of difference between replicates.
For the second experiment, a lithium heparin plasma pool containing insoluble fibrin was centrifuged at 100 rpm for 1 min to concentrate the fibrin, and the remaining procedure was as previously published [2] . The only difference was that the specimen was analyzed 10 times from the same cup rather than 5 times from 5 different aliquots/cups. The results are shown in Table 2 , which indicate that even with the wash process changes that have been implemented by Beckman, robustness has not been optimized to eliminate cross-linkage of the assay antibodies; hence, insoluble fibrin can cause falsepositive troponin results. As fibrin settles in the specimen, results approach the same values as those of the fibrin-free aliquot. Furthermore, the results of the low pool between the different runs showed a wider range of concentrations on DxI800 than that on Access 2, which suggest that the precision of Access 2 in this study was at least higher than that of DxI800. In our hospital, use of lithium heparin plasma has been further reduced from approximately 40% to approximately 25%. Lithium heparin plasma use is predominantly for renal, cardiac, and critical care clinical units, e.g., intensive care patients. This decrease in use of lithium heparin plasma should theoretically decrease the occurrence of insoluble fibrin problem. It must be kept in mind that serum specimens do present with latent clotting, as microclots (pockets of clots or strings of clots stretching across the tube) may not be always detected by the clot detection mechanism of the analyzers, and these clots can cause similar cTnI assay accuracy problems.
The data from these experiments provide strong evidence that the AccuTnI+3 assay is likely to have falsepositive cTnI results due to carryover and the presence of insoluble fibrin. Based on results to date the false-positive frequency is 2/1500, one due to sample quality/assay robustness and one considered to be due to heterophile antibodies. Therefore, more extensive studies under different conditions and in different laboratories should be performed to provide stronger evidence on potential error rate. Hence, laboratories will need to maintain vigilance and appropriate practices to minimize incorrect results until such data become available.
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